Gastrin-releasing peptide (GRP) analogues for cancer imaging

Cancer Biotherapy and Radiopharmaceuticals

Volumn 19, Issue 2, 2004, Pages 219-229

  Varvarigou, Alexandra ^a   Bouziotis, Penelope ^a   Zikos, Christos ^a   Scopinaro, Francesco ^b   De Vincentis, Giuseppe ^b  

^a INSTITUTE OF NANOSCIENCE AND NANOTECHNOLOGY   (Greece)

^b SAPIENZA UNIVERSITY OF ROME   (Italy)

Author keywords

Bombesin (BN); Cancer cell growth factors; Gastrin releasing peptide (GRP); Neurotransmitters; Radiolabeled neuropeptides

Indexed keywords

1,4,7,10 TETRAAZACYCLODODECANE 1,4,7,10 TETRAACETIC ACID; BOMBESIN DERIVATIVE; BOMBESIN RE 188; BOMBESIN RECEPTOR 1; BOMBESIN RECEPTOR 2; BOMBESIN RECEPTOR 3; BOMBESIN RECEPTOR 4; BOMBESIN[1 PROLINE 4 TYROSINE] PENTETIC ACID; BOMBESIN[13 LEUCINE] TC 99M; BOMBESIN[3 LYSINE] DIAMINODITHIOL TC 99M; BOMBESIN[4 TYROSINE] I 125; G PROTEIN COUPLED RECEPTOR; GASTRIN RELEASING PEPTIDE DERIVATIVE; GASTRIN RELEASING PEPTIDE[14-27]; INDIUM 111; IODINE 125; LUTETIUM; METHOXY ISOBUTYL ISONITRILE TECHNETIUM TC 99M; NEUROMEDIN 30; NEUROMEDIN 32; NEUROMEDIN B; NEUROMEDIN C; NEUROPEPTIDE; PENTETIC ACID; PENTETREOTIDE IN 111; PROMETHIUM; RADIOPHARMACEUTICAL AGENT; RANATENSIN; RP 527; UNCLASSIFIED DRUG; UNINDEXED DRUG;

BREAST CANCER; CANCER LOCALIZATION; CANCER SCINTISCANNING; CONFERENCE PAPER; DIGESTIVE SYSTEM CANCER; DRUG UPTAKE; HUMAN; ISOTOPE LABELING; LUNG NON SMALL CELL CANCER; NONHUMAN; PANCREAS CANCER; PRIORITY JOURNAL; PROSTATE CANCER; RADIOIODINATION; RADIOISOTOPE DISTRIBUTION;

GASTRIN-RELEASING PEPTIDE; HUMANS; NEOPLASMS; RADIOPHARMACEUTICALS;

EID: 2542506187     PISSN: 10849785     EISSN: None     Source Type: Journal    
DOI: 10.1089/108497804323072002     Document Type: Conference Paper

References (66)

1. Fischman AJ, Babich JW, Strauss WH. A ticket to ride: Peptide radiopharmaceuticals. J Nucl Med 1993;34: 2253.
2. Seregni E, Chiti A, Bombardieri E. Radionuclide imaging of neuroendocrine tumors: Biological basis and diagnostic results. Eur J Nucl Med 1998;25:639.
3. 99mmTc-labeled small peptides as diagnostic radiopharmaceuticals. Chem Rev 1999;99: 2235.
4. 99mTc-labeled peptide-based radiopharmaceuticals: An overview. Nucl Med Commun 1999;20:1093.
5. Blok D, Feitsma RI, Vermeij P, et al. Peptide radiopharmaceuticals in nuclear medicine. Eur J Nucl Med 1999;26:1511.
6. Kwekkeboom D, Krenning EP, de Jong M. Peptide-receptor imaging and therapy. J Nucl Med 2000;41:1704.
7. Signore A, Annovazzi A, Chianelli M, et al. Peptide radiopharmaceuticals for diagnosis and therapy. Eur J Nucl Med 2001;28:1555.
8. Anastasi A, Erspamer V, Bucci M. Isolation and structure of bombesin and alytesin, two analogous active peptides from the skin of the European amphibians Bombina and Alytes. Experientia 1971;27:166.
9. Preston SR, Miller GV, Primrose JN. Bombesin-like peptides and cancer. Crit Rev Oncol Hematol 1996;23: 225.
10. Espramer V, Falconieri-Espramer G, Inselvini M. Some pharmacological actions of alytesin and bombesin. J Pharm Pharmacol 1970;22:275.
11. Dietrich JB. Neuropeptides, antagonists, and cell proliferation: Bombesin as an example. Cell Mol Biol 1994;40:731.
12. Orloff MS, Reeve JR Jr., Ben-Avram CM, et al. Isolation and sequence analysis of human bombesin-like peptides. Peptides 1984;5:865.
13. Van de Wiele C, Dumont F, Van Belle S, et al. Is there a role for agonist gastrin-releasing peptide-receptor radioligands in tumor imaging? Nucl Med Commun 2001;22:5.
14. Minanimo N, Kangawa K, Matsuo H. Neuromedin C: A bombesin-like peptide, identified in porcine spinal cord. Biochem Biophys Res Commun 1984;119:14.
15. Reeve JR Jr., Walsh JH, Chew P, et al. Amino acid sequences of three bombesin-like peptides from canine intestine extracts. J Biol Chem 1983;258:5582.
16. Spindel E. Mammalian bombesin-like peptides. Trends NeuroSci 1986;9:130.
17. Spindel ER, Giladi E, Brehm P, et al. Cloning and functional characterization of a complementary DNA encoding the murine fibroblast bombesin/gastrin-releasing peptide receptor. Mol Endocrinol 1990;4:1956.
18. Wada E, Way J, Shapira H, et al. cDNA cloning, characterization, and brain region-specific expression of a Neuromedin-B-preferring bombesin receptor. Neuron 1991;6:421.
19. Fathi Z, Corjay MH, Shapira H, et al. BRS-3: Novel bombesin-receptor subtype selectively expressed in testis and lung carcinoma cells. J Biol Chem 1993; 268:5979.
20. 13]bombesin distinct from the receptor for gastrin-releasing peptide: Identification of a fourth bombesin-receptor subtype (BB4). Proc Natl Acad Sci USA 1995;92:6205.
21. Mantey SA, Weber HC, Sainz E, et al. Discovery of a high-affinity radioligand for human orphan receptor, bombesin-receptor subtype 3, which demonstrates that it has a unique pharmacology compared with other mammalian bombesin receptors. J Biol Chem 1997; 272:26062.
22. Pradham TK, Katsuno T, Taylor JE, et al. Identification of a unique ligand which has high affinity for all four bombesin-receptor subtypes. Eur J Pharmacol 1998; 343:275.
23. Kiaris H, Schally AV, Sun B, et al. Inhibition of growth of human malignant glioblastoma in nude mice by antagonists of bombesin/ gastrin-releasing peptide. Oncogene 1999;18:7168.
24. Moody TW, Desmond NC, Cutitta F, et al. High-affinity receptors for bombesin GRP-like peptides for human small-cell lung carcinoma. Life Sciences 1985;37: 105.
25. Chatzistamou I, Schally AV, Sun B, et al. Inhibition of growth of OV-1063 human epithelial ovarian cancers and c-jun and c-fos oncogene expression by bombesin antagonists. Br J Cancer 2000;83:906.
26. Charitopoulos KN, Lazaris AC, Aroni K, et al. Immunodetection of gastrin-releasing peptide in malignant melanoma cells. Melanoma Res 2000;10:345.
27. Rider NM, Guha S, Hines OJ, et al. G-protein-coupled receptor signaling in human ductal pancreatic cancer cells: Neurotension responsiveness and mitogenic stimulation. J Cell Physiol 2001;186:53.
28. Sun B, Schally AV, Halmos G. The presence of receptors for bombesin/GRP and mRNA for three receptor subtypes in human ovarian epithelial cancers. Regul Pept 2000;90:77.
29. Pansky A, de Weert A, Fasler E, et al. Gastrin-releasing peptide-preferring bombesin receptors mediate growth of human renal cell carcinoma. J Am Soc Nephrol 2000;11:1409.
30. Markwalder R, Reubi JC. Gastrin-releasing peptide receptors in the human prostate: Relation to neoplastic transformation. Cancer Res 1999;59:1152.
31. Halmos G, Wittliff JL, Schally AV. Characterization of bombesin/gastrin-releasing receptors in human breast cancer and their relationship to steroid receptor expression. Cancer Res 1995;55:280.
32. Vigh J, Lenard L, Fekete F, et al. Bombesin injection into the central amygdala influences feeding behavior in the rat. Peptides 1999;20:437.
33. Siegfried JM, Krishnamachary N, Gaither DA, et al. Evidence of autocrine actions of Neuromedin-B and gastrin-releasing peptide in non-small-cell lung cancer. Pulm Pharmacol Ther 1999;12:291.
34. Cuttitta F, Carney DN, Mulshine J, et al. Bombesin-like peptides as autocrine growth factors in human small-cell lung cancer. Nature 1985;16:823.
35. Benya RV, Kusui T, Pradhan TK, et al. Expression and characterization of cloned human bombesin receptors. Mol Pharmacol 1995;268:G24.
36. Yamada K, Ohki-Hamazaki H, Wada K. Differential effects of social isolation upon body weight, food consumption, and responsiveness to novel and social environment in bombesin-receptor subtype 3 (BRS3)-deficient mice. Physiol Behav 2000;68:555.
37. Weber HC, Walters J, Leyton JJ, et al. A bombesin-receptor subtype 3 peptide increases nuclear oncogene expression in a MEK-1-dependent manner in human lung cancer. Eur J Pharmacol 2001;412:13.
38. Polonowsky A, Shally AV, Varga JL, et al. Potentiation of the inhibitory effect of growth hormone-releasing hormone antagonists on PC-3 human prostate cancer by bombesin antagonists indicative of interference with both IGF and EGF pathways. Prostate 2000;44: 172.
39. Rozengurt F. Convergent signalling in the action of integrins, neuropeptides, growth factors, and oncogenes. Cancer Surv 1995;24:81.
40. Pranzel N, Zwick E, Daub H, et al. EGF-receptor transactivation by G-protein-coupled receptors requires metalloproteinase cleavage of proHB-EGF. Nature 1999; 402:884.
41. Zhukova F, Sinnett-Smith J, Rozengurt F. Protein kinase D protentiates DNA synthesis and cell proliferation induced by bombesin, vasopressin, or phorbolesters in Swiss 3T3 cells. J Biol Chem 2001;276:40298.
42. Alvaro-Alonso I, Munoz-Acedo G, Rodriguez-Martin E, et al. Bombesin induces a reduction of somatostatin inhibition of adenyl cyclase activity, Gi function, and somatostatin receptors in rat exocrine pancreas. Peptides 1999;20:723.
43. Hipkin RW, Wang Y, Schonbrunn A. Protein kinase C activation stimulates the phosphorylation and internalization of the sst2A somatostatin receptor. J Biol Chem 2000;275:5591.
44. Moody TW, Crawley JN, Jensen RT. Pharmacology and neurochemistry of bombesin-like peptides. Peptides 1982;3:559.
45. Avis I, Jett M, Kasprzyk PG, et al. Effect of gastrin-releasing peptide on the pancreatic tumor line (Capan). Mol Carcinog 1993;8(4):214.
46. Moody TW, Desmond NC, Cuttitta F, et al. High-affinity receptors for bombesin GRP-like peptides for human small-cell lung cancer. Life Sciences 1985;37:105.
47. 4-bombesin with specific receptors on normal human pancreatic membranes. Regulatory Peptides 1986;13(2):125.
48. 2 in ovarian carcinoma induced to express the gastrin-releasing peptide receptor by adenoviral vector-mediated gene transfer. J Nucl Med 38:1221.
49. Baidoo KE, Lin KS, Zhan Y, et al. Design, synthesis, and initial evaluation of high-affinity technetium bombesin analogues. Bioconjug Chem 1998;9:218.
50. 99mTc-labeled bombesin-like peptide. (abstr.) Eur J Nucl Med 1998; 25:915.
51. 99mTc-labeled bombesin-like peptide. Cancer Biother Radiopharm 2002;17(3):317.
52. 99mTc-labeling and in vivo studies of a bombesin analogue with novel water-soluble dithiadiphosphine-based bifunctional chelating agent. Bioconjug Chem 1999;10:254.
53. Van de Wiele C, Dumont F, Vanden Broecke R, et al. Technetium-99m RP527, a GRP analogue for visualisation of GRP-receptor-expressing malignancies: A feasibility study. Eur J Nucl Med 2000;27:1694.
54. 99mTc(I)-labeled bombesin analogue for imaging gastrin-releasing peptide receptor-positive tumors. Nucl Med Biol 2002;29:553.
55. 99mTc]Demobesin 1, a novel potent bombesin analogue for GRP-receptor-targeted tumor imaging. Eur J Nucl Med 2003; 30:247.
56. Breeman WA, Hofland LJ, de Jong M, et al. Evaluation of radiolabeled bombesin analogues for receptor-targeted scintigraphy and radiotherapy. Int J Cancer 1999;81(4):658.
57. 4] bombesin, a new radioligand for bombesin-receptor scintigraphy. Int J Cancer 1999;83(5):657.
58. Bouziotis P, Fani M, Pelecanou M, et al. Preparation of a new Re-186-labeled bombesin-like pentadecapeptide and evaluation in radiotherapy. Poster presentation at the European Association of Nuclear Medicine Annual Congress, Vienna, Austria, August 2002. Eur J Nucl Med Mol Imag 2002;29(S 1):P689 (abstr.)
59. Jankowsky R, Kirsch S, Reich T, et al. Solution structures of rhenium (V) oxo-peptide complexes of glycyl-glycylcysteine and cysteinylglycine as studied by capillary electrophoresis and X-ray absorption spectroscopy. J Inorg Bioch 1998;70:99.
60. Safavy A, Khazaeli MB, Qin H, et al. Synthesis of bombesin analogues for radiolabeling with rhenium-188. Cancer Supplement 1997;80:2354.
61. 2: An in vitro/in vivo assessment of the targeting ability of this new radiopharmaceutical for PC-3 human prostate cancer cells. Nucl Med Biol 2003;30:101.
62. 2. Nucl Med Biol 2002; 29:423.
63. Van de Wiele C, Dumont F, Vanden Broecke R, et al. Technetium-99m RP527, a GRP analogue for visualization of GRP-receptor-expressing malignancies: A feasibility study. Eur J Nucl Med 2000;27:1694.
64. Scopinaro F, Varvarigou AD, Ussof W, et al. Technetium-labeled bombesin-like peptide: Preliminary report on breast cancer uptake in patients. Cancer Biother Radipharm 2002;17(3):327.
65. 99mTc-Bombesin: A preliminary report. Tumori 2002;88(3):S25.
66. 13]Bombesin as cancer-seeking agent: Possible scintigraphic guide for surgery? Tumori 2002;88(3):S28.